MS patients switch drugs to save immune defenses
NCT ID NCT07625800
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study follows 115 adults with multiple sclerosis who are switching from ocrelizumab to ofatumumab because their antibody levels dropped. Researchers want to see if the switch stops or slows that decline over 24 months. The goal is to better manage immune health while still treating MS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ofatumumab (Kesimpta)
- What this could lead to
- If successful, this could show that switching to ofatumumab helps maintain immune function while still controlling multiple sclerosis.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all MS patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Lille
Lille, 59000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?